Neurocrine Biosciences Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 3711.02, 4298.56, 4816.25, 4889.38, 5285.32 ], "ebit_estimate": [ 979.04, 1320.14, 1726.44, 1775.62, 2053.21 ], "ebitda_estimate": [ 943.31, 1211.65, 1573.19, 1765.3, 1964.2 ], "net_income_estimate": [ 787.18, 1040.03, 1343.96, 1382.7, 1617.38 ], "per_share_eps_estimate": [ 7.47, 9.8, 12.54, 12.51, 14.59 ], "eps_nri_estimate": [ 7.57, 9.53, 12.06, 12.46, 14.56 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 38.36, 49.75, 63.21, 82.64, 98.83 ], "pretax_income_estimate": [ 1073.18, 1379.95, 1788.57, 1850.26, 2140.24 ], "operating_cash_flow_per_share_estimate": [ 9.12, 13.01, 16.23, 15.65, 17.11 ], "roa_estimate": [ 17.2, 13.4, 14.8, 12.1, 11.7 ], "roe_estimate": [ 25.27, 22.06, 22.23, 17.05, 15.5 ], "gross_margin_estimate": [ 97.9, 97.53, 97.27, 96.66, 96.24 ], "operating_cash_flow_estimate": [ 943.42, 1345.23, 1677.84, 1618.21, 1768.66 ], "pettm_estimate": [ 23.73, 18.08, 14.13, 14.17, 12.14 ], "long_term_growth_rate_mean": 36.01, "long_term_revenue_growth_rate_mean": "18.65", "future_per_share_eps_estimate_growth": 38.21, "future_eps_nri_estimate_growth": 36.01, "future_revenue_estimate_growth": 18.65, "future_ebit_estimate_growth": 40.15, "future_ebitda_estimate_growth": 33.72, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 40.16, "future_pretax_income_estimate_growth": 35.56, "future_book_value_per_share_estimate_growth": 25.3, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -0.32, "future_operating_cash_flow_per_share_estimate_growth": 30.09 }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 875.76, 992.48, 1025.78, 1041.53, 1116.73, 1162.79, 1191.11 ], "ebit_estimate": [ 207.27, 289.17, 291.57, 280.99, 343.49, 380.54, 385.3 ], "ebitda_estimate": [ 221.02, 295.24, 300.22, null, null, null, null ], "net_income_estimate": [ 156.45, 212.18, 208.31, 234.48, 248.69, 277.5, 281.41 ], "per_share_eps_estimate": [ 1.59, 2.08, 2.02, 1.94, 2.38, 2.67, 2.7 ], "eps_nri_estimate": [ 1.56, 2.1, 2.03, 2.07, 2.42, 2.66, 2.76 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ 34.5, 36.61, 38.81, null, null, null, null ], "pretax_income_estimate": [ 220.19, 299.44, 297.54, 281.04, 343.57, 381.36, 386.75 ], "operating_cash_flow_per_share_estimate": [ 6.16, 1.28, 2.45, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ 17.99, 22.39, 18.87, null, null, null, null ], "gross_margin_estimate": [ 98.19, 98.15, 98.12, 98, 98, 98, 98 ], "operating_cash_flow_estimate": [ 637.29, 132.35, 253.33, null, null, null, null ], "pettm_estimate": [ 23.23, 21.03, 19.67, 18.29, null, null, null ], "long_term_growth_rate_mean": 36.01, "long_term_revenue_growth_rate_mean": "18.65", "future_per_share_eps_estimate_growth": 38.21, "future_eps_nri_estimate_growth": 36.01, "future_revenue_estimate_growth": 18.65, "future_ebit_estimate_growth": 40.15, "future_ebitda_estimate_growth": 33.72, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 40.16, "future_pretax_income_estimate_growth": 35.56, "future_book_value_per_share_estimate_growth": 25.3, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -0.32, "future_operating_cash_flow_per_share_estimate_growth": 30.09 }